Sanford-Burnham Medical Research Institute announced Monday it will collaborate with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer’s disease and major psychiatric disorders.
Dr. John Reed, CEO of Sanford-Burnham, said the agreement is the first of a series of collaborations “that focus our tremendous scientific and translational firepower on major unmet medical problems. Working in concert with strong partners, we can bridge the gap between early- and late-stage drug development,”
Under the agreement, teams from Sanford-Burnham and OMJPI will work to identify and validate new targets for drug discovery and will seek compounds suitable for lead optimization and further development by OMJPI. The La Jolla-based institute also will receive funding, including upfront and yearly access fees, funding of discovery research in the field, milestone payments and royalties for successfully developed products.
OMJPI gains exclusive access for a three-year term to a multi-disciplinary team of world-class scientists and a translational infrastructure dedicated to finding new approaches to treating patients with devastating neurological and psychiatric conditions.
A joint steering committee will oversee the collaboration, which includes a drug discovery team funded by OMJPI in the Conrad Prebys Center for Chemical Genomics (CPCCG) at Sanford-Burnham. The center was established by the National Institutes of Health as part of a national effort to accelerate the rate of commercialization of basic research by generating small molecule probes that can be used to develop a pipeline of drugs to treat unmet medical needs.
“This agreement sets the stage for Sanford-Burnham to fully leverage the drug discovery infrastructure the Institute has put into place over the last five years,” said Dr. Michael Jackson, Vice President, Drug Discovery and Development at Sanford-Burnham.